Mapping serotonergic activity after an oral challenge with the SSRI citalopram using pharmacologic Magnetic Resonance Imaging (phMRI)

Mapping serotonergic activity after an oral challenge with the SSRI citalopram using pharmacologic Magnetic Resonance Imaging (phMRI) - Oral 5-HT phMRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32645

Enrollment

Registered

2009-11-26

Start date

2009-10-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

geen none

Interventions

-Non-invasive 3.0 Tesla MR imaging of cerebral hemodynamics on six different time points. Twice following administration of the SSRI citalopram (16 mg, oral solution) and one following administratio

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male, 20-30 years old, right-handed, healthy

Exclusion criteria

Exclusion criteria: The presence of metal in the body (e.g. osteosynthetic material, pacemaker, artificial cardiac valves, dental braces) or other contraindications to MR imaging; claustrophobia; known or symptomatic brain disease, psychiatric or neurological disorders; current or previous treatment with medications that influence the 5-HT system (SSRIs, methylphenidate, sleep aids etc.); contraindications to citalopram treatment (known hypersensitivity to one of the contents, use of other SSRIs or pimozide (Orap), thioridazine or monoamine oxidase inhibitors (MAOI)); current or past drug (ab)use, excessive consumption of alcohol (>21 units/week), caffeine (> 8 cups/day) or nicotine (>10 cigarettes/day).

Design outcomes

Primary

Measure	Time frame
Resting-state phMRI: - % change in resting-state fMRI signal compared to baseline in 5-HT related regions of interest (ROIs) Task-related phMRI: - % change in task-related fMRI signal from baseline in ROIs related to the specific tasks - Differences in % change between resting-state and task-related phMRI scans, between ALS- and BOLD-based resting-state signal and between the four different task-related signals - Differences in % change between the citalopram-challenged phMRI scan sessions and the placebo scan session.	—

Measure

Time frame

Resting-state phMRI: - % change in resting-state fMRI signal compared to baseline in 5-HT related regions of interest (ROIs) Task-related phMRI: - % change in task-related fMRI signal from baseline in ROIs related to the specific tasks - Differences in % change between resting-state and task-related phMRI scans, between ALS- and BOLD-based resting-state signal and between the four different task-related signals - Differences in % change between the citalopram-challenged phMRI scan sessions and the placebo scan session.

—

Secondary

Measure	Time frame
- Test-retest ability: difference in % change between the two citalopram-challenged phMRI scan sessions - % change in cognitive performance on emotional face recognition task, Go/No-go task, reward task and motor task between the three different phMRI scan sessions and between the three baseline scan sessions (to exclude order effects)	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)